NASDAQ:EPIX ESSA Pharma (EPIX) Stock Price, News & Analysis $1.83 +0.07 (+3.98%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About ESSA Pharma Stock (NASDAQ:EPIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ESSA Pharma alerts:Sign Up Key Stats Today's Range$1.73▼$1.8650-Day Range$1.40▼$7.0052-Week Range$1.40▼$11.67Volume360,732 shsAverage Volume2.47 million shsMarket Capitalization$81.20 millionP/E RatioN/ADividend YieldN/APrice Target$11.67Consensus RatingHold Company OverviewESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More… New post-election stock warning from Wall Street (Ad)If you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first time in history...Not everything is as rosy as it seems on Wall Street. ESSA Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreEPIX MarketRank™: ESSA Pharma scored higher than 52% of companies evaluated by MarketBeat, and ranked 550th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingESSA Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageESSA Pharma has only been the subject of 3 research reports in the past 90 days.Read more about ESSA Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ESSA Pharma are expected to grow in the coming year, from ($0.70) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ESSA Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.59% of the outstanding shares of ESSA Pharma have been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldESSA Pharma does not currently pay a dividend.Dividend GrowthESSA Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.59% of the outstanding shares of ESSA Pharma have been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for ESSA Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for EPIX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows1 people have added ESSA Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,076,665.00 in company stock.Percentage Held by Insiders14.70% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ESSA Pharma's insider trading history. Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EPIX Stock News HeadlinesGrowth N. V. Biotech Sells 7,879,583 Shares of ESSA Pharma Inc. (NASDAQ:EPIX) StockNovember 6, 2024 | insidertrades.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIXNovember 18, 2024 | prnewswire.comJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 24, 2024 | Priority Gold (Ad)Piper Sandler Downgrades ESSA Pharma (EPIX)November 6, 2024 | msn.comOppenheimer Downgrades ESSA Pharma (EPIX)November 6, 2024 | msn.comESSA Pharma Downgraded to Hold Amid Masofaniten Trial Termination and Revised Financial OutlookNovember 4, 2024 | markets.businessinsider.comEssa Pharma downgraded to Perform from Outperform at OppenheimerNovember 4, 2024 | markets.businessinsider.comESSA Pharma Faces Uncertainty After Discontinuing Masofaniten Programs, Receives Hold RatingNovember 3, 2024 | markets.businessinsider.comSee More Headlines EPIX Stock Analysis - Frequently Asked Questions How have EPIX shares performed this year? ESSA Pharma's stock was trading at $6.60 on January 1st, 2024. Since then, EPIX stock has decreased by 72.3% and is now trading at $1.83. View the best growth stocks for 2024 here. How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc. (NASDAQ:EPIX) issued its earnings results on Monday, August, 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.10. Who are ESSA Pharma's major shareholders? Top institutional investors of ESSA Pharma include Bellevue Group AG (17.76%), RTW Investments LP (7.35%), PFM Health Sciences LP (6.18%) and Parkman Healthcare Partners LLC (0.78%). Insiders that own company stock include David Ross Parkinson, Peter Virsik and Growth N V Biotech. View institutional ownership trends. How do I buy shares of ESSA Pharma? Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Jabil (JBL), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings8/05/2024Today11/23/2024Next Earnings (Estimated)12/10/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EPIX CUSIPN/A CIK1633932 Webwww.essapharma.com Phone778-331-0962Fax604-738-4080Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$11.67 High Stock Price Target$17.00 Low Stock Price Target$2.00 Potential Upside/Downside+537.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.17% Return on Assets-19.62% Debt Debt-to-Equity RatioN/A Current Ratio36.95 Quick Ratio36.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.30 per share Price / Book0.55Miscellaneous Outstanding Shares44,370,000Free Float37,847,000Market Cap$81.20 million OptionableOptionable Beta1.84 Social Links 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:EPIX) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.